勃林格殷格翰启动首个人用药中国本地化生产，中国生物制药CEO谢承润出席仪式

Core Points - Boehringer Ingelheim has officially launched the local production of its diabetes drug, Onglyza (linagliptin), in China, marking the company's first local production of a human medication in the country [1] - The local production plan is expected to significantly enhance the supply stability of Onglyza in the Chinese market [1] - The CEO of China National Pharmaceutical Group, Xie Chengrun, attended the launch ceremony, indicating a partnership between Boehringer Ingelheim and the Chinese biopharmaceutical company [1]